Permanent His bundle pacing to replace biventricular pacing for cardiac resynchronization therapy.
Benjamin J Scherlag1, Alexa Papaila1
1Heart Rhythm Institute, Division of Cardiology, Department of Medicine, Oklahoma University Health Sciences Center, United States.
Medical Hypotheses
|November 19, 2017
Summary
Permanent His bundle pacing (PHBP) offers a more physiological approach to ventricular pacing compared to standard biventricular pacing (BIVP). This method may improve outcomes in heart failure patients, particularly those with narrow QRS durations.
Area of Science:
- Cardiology
- Electrophysiology
- Medical Devices
Background:
- Cardiac resynchronization therapy (CRT) using biventricular pacing (BIVP) treats heart failure with ventricular dyssynchrony, especially in patients with wide QRS durations (>150ms).
- A significant portion of heart failure patients with dyssynchrony and narrower QRS durations (<130ms) do not respond well to standard CRT.
- Permanent His bundle pacing (PHBP) is emerging as an alternative pacing strategy.
Purpose of the Study:
- To hypothesize that standard BIVP is spatially and temporally abnormal.
- To propose that PHBP is the most physiological pacing method, mimicking normal cardiac conduction.
- To suggest that a comparative trial will demonstrate PHBP's efficacy in heart failure patients with QRS durations >130ms and potential benefit in those with QRS <130ms.
Main Methods:
- Review of experimental and clinical evidence supporting the hypotheses.
- Proposed prospective, crossover trial comparing PHBP and BIVP.
- Focus on QRS duration normalization and heart failure outcomes.
Main Results:
- BIVP leads to abnormal spatial and temporal ventricular activation.
- PHBP replicates normal interventricular conduction patterns.
- Evidence suggests PHBP may offer benefits across a broader QRS duration spectrum.
Conclusions:
- PHBP represents a more physiological alternative to BIVP for CRT.
- PHBP has the potential to improve outcomes in heart failure patients, including non-responders to standard CRT.
- Further clinical trials are warranted to confirm the benefits of PHBP.
Related Concept Videos
Heart Failure VI: Adjunct Therapies
417
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
417
Cardiomyopathy II: Dilated Cardiomyopathy
608
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
608
Pulse rhythm
1.5K
Pulse rhythm refers to the pattern of pulsations within specific intervals, offering valuable insights into the regularity or irregularity of the heart's beats as observed through the pattern of pulsation within specific intervals. A regular pulse exhibits a consistent heart rate with uniform waveforms and pulsation force, variations of which can be classified as normal, weak, or bounding.
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
Conversely, an irregular pulse pattern is termed dysrhythmia, stemming from disruptions in cardiac...
1.5K
Heart Failure Drugs: Inotropic Agents
1.6K
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
1.6K
Dysrhythmias VI: Management of Dysrhythmias
509
Dysrhythmia management involves a multifaceted approach, incorporating pharmacological treatments, medical procedures, surgical interventions, lifestyle modifications, and patient education.Pharmacological ManagementAntiarrhythmic Drugs:Class I (Sodium Channel Blockers): This class includes quinidine and procainamide, which reduce the speed of impulse conduction in the heart, stabilize the cardiac membrane, and control arrhythmias. Quinidine and procainamide are Class IA agents that prolong the...
509
Conduction System of the Heart
13.9K
Autorhythmicity is a term that refers to the heart's inherent ability to generate electrical signals and instigate muscle contractions. This self-regulating conduction system within the heart consists of two key components: the pacemaker cells and specialized conducting cells.
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
The pacemaker cells are located in two primary nodes: the sinoatrial (SA) node and the atrioventricular (AV) node. The SA node pacemaker cells can autonomously depolarize, triggering an action potential that leads to the...
13.9K


